Acrivon Therapeutics, Inc. (ACRV) intrinsic value & 10-year financials
Acrivon Therapeutics, Inc. (ACRV) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.64
- Market cap
- $63.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -84.2%
- Free cash flow (FY2025)
- -$65.3M
ACRV 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$77.9M | -$2.02 | -$65.3M | — | -79.3% |
| FY2024 | — | -$80.6M | -$2.38 | -$68.4M | — | -70.5% |
| FY2023 | — | -$60.4M | -$2.74 | -$43.9M | — | -51.6% |
| FY2022 | — | -$31.2M | -$7.56 | -$32.3M | — | -233.1% |
| FY2021 | — | -$16.2M | -$9.32 | -$14.2M | — | 13.7% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Acrivon Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Acrivon Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -38.0% ROIC.
Acrivon Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Acrivon Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.